ClinicalTrials.Veeva

Menu
The trial is taking place at:
C

CenExel Clinical Research | JBR Clinical Research

Veeva-enabled site

A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

Status and phase

Enrolling
Phase 4

Conditions

Acute Pain

Treatments

Drug: Suzetrigine

Study type

Interventional

Funder types

Industry

Identifiers

NCT06887972
VX24-548-113

Details and patient eligibility

About

The purpose of this study to evaluate the effectiveness, safety, and tolerability of SUZ as part of multimodal therapy (MMT) in treating acute postoperative pain.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Body mass index (BMI) of greater than or equal to (≥)18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m^2)
  • Participants scheduled to undergo an aesthetic or reconstructive surgical procedure that would typically be treated with opioid therapy for at least 72 hours postoperatively

Key Exclusion Criteria:

• Participated in a previous study with SUZ or received Journavx

Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

100 participants in 1 patient group

Suzetrigine (SUZ)
Experimental group
Description:
Participants will receive SUZ for 14 days or until their pain resolves, whichever occurs first.
Treatment:
Drug: Suzetrigine

Trial contacts and locations

4

Loading...

Central trial contact

Medical Information

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems